Screener
Kura Oncology KURA Contract Liabilities
Contract Liabilities at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | March 31, 2026 | December 31,2025 |
|---|---|---|
| Long-term debt, net | 9,749 | 9,711 |
| Long-term operating lease liabilities | 13,241 | 9,469 |
| Other long-term liabilities | 3,437 | 3,165 |
| Long-term contract liabilities | 416,745 | 424,909 |
| Total liabilities | 544,668 | 564,228 |
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.0001 par value; 200,000 shares authorized; 88,763 and 87,855 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 9 | 9 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's contract liabilities?
- Kura Oncology (KURA) reported contract liabilities of $416.75M in Q1 2026.
- How has Kura Oncology's contract liabilities changed year-over-year?
- Kura Oncology's contract liabilities increased by 53.3% year-over-year, from $271.93M to $416.75M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Kura Oncology's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude